Clinical Trials Browser

Leukemia × ruxolitinib × 90 days × Clear all

Burkitt Lymphoma, Leukemia

NCT07464951 2026-03-11

CART123

Phase 1 Not yet recruiting

30 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT07356245 2026-01-21

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Phase 2 Recruiting

44 enrolled

DermatologicLymphoidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06768476 2026-01-16

AML

Phase 1 Active not recruiting

12 enrolled

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT07249346 2025-12-24

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Phase 2 Recruiting

124 enrolled

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Leukemia, Myelomonocytic, Chronic

Clinical Trials

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

CART123

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

AML

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation